Advanz Pharma Corp. Limited, a specialty pharmaceutical company with a strategic focus on complex medicines in Europe, made several changes in senior leadership roles as it enters the next phase of its growth journey.
Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, appointed Zack McGahey as chief operating officer.
Provention Bio Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, appointed Jan Hillson, M.D., as senior VP of Clinical Development.
Blue Water Vaccines Inc., a biopharmaceutical company, named Dr. Ronald R. Cobb its head of Science and Discovery.
Amphista Therapeutics, a leader in next-generation targeted protein degradation approaches, made Beverley Carr the company’s chief business officer.
Photocure ASA, the Bladder Cancer Company, made Anders Neijber VP, Global Medical Affairs and Clinical Development.
HCPs today are playing a game with which many medical affairs teams are not familiar.
With data proliferating rapidly in the biopharma industry, commercial teams need to harness this data to accurately track prescription pull-through from sales and marketing activities and understand the return on their promotional investments.
The interplay of communication channels – websites, e-mail, video, podcast, social media, mass media, and, of course, interpersonal – is all the rage in consumer marketing today. Hundreds of millions of marketing dollars are being committed to these channels each year – and marketing spend is expected to grow by nearly 15 percent this year, according to Deloitte.
When seeking to understand why patients aren’t adherent to treatment or which barriers are impeding their access to health care, do you ask about their environment? This isn’t just finding out their ZIP code, although that’s part of it. Recognizing the impact of environmental factors helps us better understand how to reach and connect with patients as people.
